Effect of 5% dextrose water injection compared to corticosteroid injection to improve clinical symptoms and performance of patients with mild to moderate carpal tunnel syndrome

Comparison of the Effect of 5% Dextrose Water Injection with Corticosteroid Injection on Improving Clinical Signs and Performance of Patients with Mild to Moderate Cartilage Tunnel Syndrome in Patients Referring to Isfahan University of Medical Sciences Clinics during 2018: A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180209038673N4

Enrollment

Registered

2019-05-16

Start date

2018-03-21

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carpal tunnel syndrome. Carpal tunnel syndrome

Interventions

Intervention 1: Intervention group A: Patients in this group were administered with acetaminophen (500 mg/ 6 hour during 2 weeks) and vitamin B6 (40 mg/daily) during 1 months. Then, patients were in

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with mild to moderate carpal tunnel syndrome

Exclusion criteria

Exclusion criteria: Patients with severe carpal tunnel syndrome Patients with methemoglobinemia, favism and severe liver disease and thyroid disease Sensitization and allergy to local anesthetics Diseases that imitate symptoms of carpal tunnel syndrome such as cervical radiculopathy, peripheral neuropathy and trauma Corticosteroid injections and physiotherapy in the last three weeks History of hand surgery in the last 6 months Having other neurological disorders

Design outcomes

Primary

Measure	Time frame
Severity of disease. Timepoint: Before treatment, 4 weeks and 12 weeks after treatment. Method of measurement: According to the questionnaire of 11 items of the severity of tunnel carpal syndrome.	—

Secondary

Measure	Time frame
Severity of disease. Timepoint: Before treatment, 4 weeks and 12 weeks after treatment. Method of measurement: According to VAS scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSafoura Aghaee

Esfahan University of Medical Sciences

saghaei826@gmail.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026